Project Grant R21AI185530
Award Date
4/25/25
Completion Date
3/31/27
Dollars Obligated
$242K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
This $2,760,350 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the fundamental pathways governing the host's ability to combat Cryptosporidium parvum infections at mucosal sites. The research project has two key objectives: establishing reliable small mouse models of cryptosporidiosis and unraveling the intricacies of IFN-γ responses during C. parvum infection....
This Project Grant award of $147,656.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to support research on the molecular architecture and function of the host-parasite interface of the Cryptosporidium parasite. The primary objectives are to uncover the three-dimensional ultrastructure, molecular composition, and transport mechanisms at the Cryptosporidium host-parasite interface using...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $852,980 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Georgia Research Foundation, Inc. The grant will fund research to examine gene regulation and post-transcriptional regulation in the Cryptosporidium parasite, a major cause of diarrheal disease. Key objectives include investigating transcriptional and translational aspects of polycistronic gene...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $813,160 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to George Washington University to develop mRNA-LNP vaccines targeting multiple stages and species of the human malaria parasite. The funding will support research to evaluate the protective efficacy of individual and combination vaccine antigens from Plasmodium falciparum and Plasmodium vivax, the two main malaria parasite species...
This federal Project Grant award, valued at $1,397,469.00 and provided by the National Institute of Allergy and Infectious Diseases (NIAID), supports a 5-year research study under the Allergy and Infectious Diseases Research program (CFDA 93.855). The study aims to identify correlates of protection (CoPs) for inactivated oral cholera vaccines in both adults and children, and to compare these vaccine-derived CoPs to those from natural Vibrio cholerae infection. The project will involve...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is focused on evaluating how differential gut microbiota populations may influence malaria vaccine-induced immune responses. The total funding amount is $934,229, awarded on June 24, 2024, with an ultimate completion date of April 30, 2026. The primary objectives are to: 1) Assess how differential murine gut microbiota...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $153,512.00 to the University of Washington to conduct research on understanding and overcoming immune evasion mechanisms of the Plasmodium parasite, which causes malaria. The research aims to characterize the memory B cell response to the circumsporozoite protein (CSP) of Plasmodium during infection and...
This Project Grant award (R21AI182639) for $205,125.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research at the Hennepin Healthcare Research Institute (HHRI) to investigate the impact of microbial exposure on the immune response and efficacy of Plasmodium whole sporozoite vaccines in a small animal model. The research aims to define the T cell and antibody responses to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $832,071 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Seattle Children's Hospital to develop a universal transmission-blocking vaccine (TBV) against multiple Plasmodium species that cause malaria. The research program aims to discover potent monoclonal antibodies that can block mosquito vector infection across Plasmodium falciparum and Plasmodium vivax, the two main human malaria parasite...
This $1,845,103 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to define the immunogenic landscape of early mosquito-stage Plasmodium falciparum parasites. The goal is to accelerate the discovery of malaria transmission-blocking vaccines. The research involves using mass spectrometry-based proteomics to comprehensively catalog surface-exposed proteins in P. falciparum...